SG11202101733TA - Small molecule menin inhibitors - Google Patents

Small molecule menin inhibitors

Info

Publication number
SG11202101733TA
SG11202101733TA SG11202101733TA SG11202101733TA SG11202101733TA SG 11202101733T A SG11202101733T A SG 11202101733TA SG 11202101733T A SG11202101733T A SG 11202101733TA SG 11202101733T A SG11202101733T A SG 11202101733TA SG 11202101733T A SG11202101733T A SG 11202101733TA
Authority
SG
Singapore
Prior art keywords
small molecule
menin inhibitors
menin
inhibitors
molecule
Prior art date
Application number
SG11202101733TA
Inventor
Shaomeng Wang
Shilin Xu
Angelo Aguilar
Liyue Huang
Tianfeng Xu
Meng Zhang
Renqi Xu
Fuming Xu
Haibin Zhou
Tao Liu
Original Assignee
Univ Michigan Regents
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents, Agios Pharmaceuticals Inc filed Critical Univ Michigan Regents
Publication of SG11202101733TA publication Critical patent/SG11202101733TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202101733TA 2018-10-03 2019-09-30 Small molecule menin inhibitors SG11202101733TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862740567P 2018-10-03 2018-10-03
US201862740561P 2018-10-03 2018-10-03
PCT/US2019/053904 WO2020072391A1 (en) 2018-10-03 2019-09-30 Small molecule menin inhibitors

Publications (1)

Publication Number Publication Date
SG11202101733TA true SG11202101733TA (en) 2021-03-30

Family

ID=68318937

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101733TA SG11202101733TA (en) 2018-10-03 2019-09-30 Small molecule menin inhibitors

Country Status (14)

Country Link
US (1) US20210353610A1 (en)
EP (1) EP3860978A1 (en)
JP (1) JP2022502409A (en)
KR (1) KR20210072787A (en)
CN (1) CN113166059A (en)
AU (1) AU2019351820A1 (en)
BR (1) BR112021006273A2 (en)
CA (1) CA3112340A1 (en)
IL (1) IL281949A (en)
MX (1) MX2021003732A (en)
PH (1) PH12021550374A1 (en)
SG (1) SG11202101733TA (en)
TW (1) TW202115017A (en)
WO (1) WO2020072391A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202126636A (en) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 Piperidine compounds as menin inhibitors
TW202204333A (en) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin inhibitors and methods of use for treating cancer
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US8242078B2 (en) 2006-10-19 2012-08-14 The University Of Chicago Therapeutics to inhibit MLL-menin interaction for treating leukemia
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
CA2904612A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US9212180B2 (en) 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
BR112018072570A2 (en) 2016-05-02 2019-02-19 Univ Michigan Regents piperidines as girl inhibitors
WO2018106820A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018183857A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
WO2019191526A1 (en) * 2018-03-30 2019-10-03 The Regents Of The University Of Michigan Piperidine compounds as covalent menin inhibitors

Also Published As

Publication number Publication date
IL281949A (en) 2021-05-31
MX2021003732A (en) 2021-08-11
WO2020072391A1 (en) 2020-04-09
KR20210072787A (en) 2021-06-17
CA3112340A1 (en) 2020-04-09
CN113166059A (en) 2021-07-23
US20210353610A1 (en) 2021-11-18
TW202115017A (en) 2021-04-16
BR112021006273A2 (en) 2021-07-06
EP3860978A1 (en) 2021-08-11
PH12021550374A1 (en) 2021-11-08
JP2022502409A (en) 2022-01-11
AU2019351820A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
IL281182A (en) Piperidines as menin inhibitors
IL277006A (en) Cd73 inhibitors
IL261557A (en) Small molecule ire1-alpha inhibitors
IL269196A (en) Novel inhibitors
EP3630748A4 (en) Ire1 small molecule inhibitors
EP3548476A4 (en) Ire1 small molecule inhibitors
IL304348A (en) Cd73 inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL281949A (en) Small molecule menin inhibitors
EP3541375A4 (en) FACTOR XIIa INHIBITORS
GB201807014D0 (en) Factor xlla inhibitors
EP3541381A4 (en) FACTOR XIIa INHIBITORS
IL281634A (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
ZA201907136B (en) Ip6k inhibitors
IL276013A (en) Pi4kiiibeta inhibitors
IL283433A (en) Ire1 small molecule inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL274550A (en) Dopamine-b-hydroxylase inhibitors
LT3632912T (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors